EVEREST MED issued 3,250 new ordinary shares in March 2026, lifting its outstanding share count to 353.58 million. The increase stemmed entirely from option exercises under the Post-IPO Share Option Scheme, generating HKD 0.05 million in proceeds. No treasury shares were created or cancelled during the month.

Authorised capital remained unchanged at 500.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to total authorised capital of USD 50,000.

Option activity centred on two legacy plans: • Post-IPO Share Option Scheme — 3,250 options were exercised and 314,798 lapsed, leaving 21.25 million options outstanding. • Pre-IPO Employee Share Option Plan — outstanding options stood at 158,573.

On 24 February 2026, shareholders approved a new 2026 Share Scheme carrying a mandate to issue or transfer up to 35.36 million shares. Following its adoption, no further grants will be made under the two earlier schemes; however, existing options under those plans remain valid. No options or share awards have yet been granted under the new scheme.

Separately, 3.29 million restricted stock units from the Pre-IPO plan and 1.61 million awards from the Post-IPO scheme remain issuable. During March, 42,925 RSUs vested and 114,834 awards were cancelled across the two legacy programmes.

The company confirmed compliance with Hong Kong’s minimum 25% public float rule at month-end.